Free Trial
NASDAQ:MBIO

Mustang Bio (MBIO) Stock Price, News & Analysis

Mustang Bio logo
$2.93 +0.02 (+0.72%)
Closing price 02/21/2025 03:59 PM Eastern
Extended Trading
$2.95 +0.02 (+0.65%)
As of 02/21/2025 07:25 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Mustang Bio Stock (NASDAQ:MBIO)

Key Stats

Today's Range
$2.88
$3.06
50-Day Range
$2.64
$12.83
52-Week Range
$2.40
$74.50
Volume
60,456 shs
Average Volume
513,261 shs
Market Capitalization
$2.81 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$100.00
Consensus Rating
Buy

Company Overview

Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-117 and MB-217, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-101 CAR T cell program for glioblastoma; MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts.

Mustang Bio Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
26th Percentile Overall Score

MBIO MarketRank™: 

Mustang Bio scored higher than 26% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Mustang Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Mustang Bio has received no research coverage in the past 90 days.

  • Read more about Mustang Bio's stock forecast and price target.
  • Earnings Growth

    Earnings for Mustang Bio are expected to grow in the coming year, from ($35.00) to ($19.50) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Mustang Bio is -0.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Mustang Bio is -0.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Mustang Bio has a P/B Ratio of 4.37. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Mustang Bio's valuation and earnings.
  • Percentage of Shares Shorted

    11.35% of the float of Mustang Bio has been sold short.
  • Short Interest Ratio / Days to Cover

    Mustang Bio has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Mustang Bio has recently increased by 243.51%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Mustang Bio does not currently pay a dividend.

  • Dividend Growth

    Mustang Bio does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    11.35% of the float of Mustang Bio has been sold short.
  • Short Interest Ratio / Days to Cover

    Mustang Bio has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Mustang Bio has recently increased by 243.51%, indicating that investor sentiment is decreasing significantly.
  • Search Interest

    Only 2 people have searched for MBIO on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.
  • MarketBeat Follows

    Only 2 people have added Mustang Bio to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Mustang Bio insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 0.45% of the stock of Mustang Bio is held by insiders.

  • Percentage Held by Institutions

    Only 9.95% of the stock of Mustang Bio is held by institutions.

  • Read more about Mustang Bio's insider trading history.
Receive MBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mustang Bio and its competitors with MarketBeat's FREE daily newsletter.

MBIO Stock News Headlines

Buy this AI Stock Before Elon’s Announcement
With Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dust. This isn't just a prediction; it's a calculated shift backed by political support, policy changes, and Musk's proven track record. I've identified a company that is quietly enabling xAI's rapid growth.
Mustang Bio regains compliance with Nasdaq
Mustang Bio Announces Pricing of $8 Million Public Offering
Mustang Bio prices 2.66M shares at $3.01 in public offering
See More Headlines

MBIO Stock Analysis - Frequently Asked Questions

Mustang Bio's stock was trading at $8.85 at the start of the year. Since then, MBIO stock has decreased by 66.9% and is now trading at $2.9310.
View the best growth stocks for 2025 here
.

Mustang Bio, Inc. (NASDAQ:MBIO) posted its quarterly earnings results on Friday, November, 8th. The company reported ($2.00) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($6.50) by $4.50.

Shares of Mustang Bio reverse split on the morning of Thursday, January 16th 2025. The 1-50 reverse split was announced on Tuesday, January 14th 2025. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, January 15th 2025. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

Mustang Bio's top institutional investors include Geode Capital Management LLC (29.63%) and Concourse Financial Group Securities Inc..
View institutional ownership trends
.

Shares of MBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Mustang Bio investors own include BMO Capital Markets (), Stifel Nicolaus (), Wunderlich (), Standpoint Research (), Duncan Williams (), Soleil Securities () and Sterne Agee CRT ().

Company Calendar

Last Earnings
11/08/2024
Today
2/21/2025
Next Earnings (Estimated)
3/10/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:MBIO
Fax
N/A
Employees
100
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$100.00
High Stock Price Target
$100.00
Low Stock Price Target
$100.00
Potential Upside/Downside
+3,311.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-51,600,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.67 per share

Miscellaneous

Free Float
952,000
Market Cap
$2.81 million
Optionable
Not Optionable
Beta
1.73
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, Starlink, or X.AI? Enter your email address to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

This page (NASDAQ:MBIO) was last updated on 2/22/2025 by MarketBeat.com Staff
From Our Partners